Coverage Denials Eyed in HCV Rx Nonstarts

From the "Tell me something I don't already know department"! Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014. As of 2016, more than one-third of patients prescribed DAA treatm